Gilead Sciences, Inc.
General ticker "GILD" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $134.7B (TTM average)
Gilead Sciences, Inc. follows the US Stock Market performance with the rate: 46.1%.
Estimated limits based on current volatility of 1.5%: low 121.48$, high 125.12$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Company pays dividends (quarterly): last record date 2025-12-15, amount 0.79$ (Y2.53%)
- Total employees count: 17600 (-2.2%) as of 2024
- US accounted for 37.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Climate change and natural disasters, Regulatory and compliance, Proposed legislation impacting operations, Anti bribery laws, Intellectual property risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [85.07$, 115.87$]
- 2025-12-31 to 2026-12-31 estimated range: [98.12$, 131.58$]
Financial Metrics affecting the GILD estimates:
- Negative: with PPE of 20.1 at the end of fiscal year the price was high
- Positive: -5.02 < Operating profit margin, % of 5.78
- Positive: 6.63 < Operating cash flow per share per price, % of 9.36
- Positive: 5.42 < Industry operating cash flow per share per price (median), % of 7.82
- Positive: Industry earnings per price (median), % of 5.62 > 4.45
- Positive: Industry operating profit margin (median), % of 20 > 9.53
- Positive: -3.57 < Return on assets ratio (scaled to [-100,100]) of 0.81
- Positive: Industry inventory ratio change (median), % of -0.49 <= -0.18
Short-term GILD quotes
Relationship graph
Long-term GILD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $27,281.00MM | $27,116.00MM | $28,754.00MM |
| Operating Expenses | $19,951.00MM | $19,511.00MM | $27,092.00MM |
| Operating Income | $7,330.00MM | $7,605.00MM | $1,662.00MM |
| Non-Operating Income | $-1,516.00MM | $-746.00MM | $-972.00MM |
| Interest Expense | $935.00MM | $944.00MM | $977.00MM |
| R&D Expense | $4,977.00MM | $5,718.00MM | $5,907.00MM |
| Income(Loss) | $5,814.00MM | $6,859.00MM | $690.00MM |
| Taxes | $1,248.00MM | $1,247.00MM | $211.00MM |
| Profit(Loss)* | $4,592.00MM | $5,665.00MM | $480.00MM |
| Stockholders Equity | $21,240.00MM | $22,833.00MM | $19,330.00MM |
| Inventory | $1,507.00MM | $1,787.00MM | $1,710.00MM |
| Assets | $63,171.00MM | $62,125.00MM | $58,995.00MM |
| Operating Cash Flow | $9,072.00MM | $8,006.00MM | $10,828.00MM |
| Capital expenditure | $728.00MM | $585.00MM | $523.00MM |
| Investing Cash Flow | $-2,466.00MM | $-2,265.00MM | $-3,449.00MM |
| Financing Cash Flow | $-6,469.00MM | $-5,125.00MM | $-3,433.00MM |
| Earnings Per Share** | $3.66 | $4.54 | $0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.